Cargando…

Botulinum Toxin in Neurogenic Detrusor Overactivity

PURPOSE: To evaluate the effects of botulinum toxin on urodynamic parameters and quality of life in patients with neurogenic detrusor overactivity. METHODS: Thirty four adult patients with spinal cord injury and detrusor overactivity were selected. The patients received 300 units of botulinum toxin...

Descripción completa

Detalles Bibliográficos
Autores principales:	D'Ancona, Carlos Arturo Levi, Ferreira, Rúiter Silva, Rassi, Mauricio Carneiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Continence Society 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3469833/ https://www.ncbi.nlm.nih.gov/pubmed/23094220 http://dx.doi.org/10.5213/inj.2012.16.3.139

Ejemplares similares

Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial
por: Ferreira, Rúiter Silva, et al.
Publicado: (2018)

Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity
por: Cho, Young Sam, et al.
Publicado: (2016)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
por: Wu, Shang-Jun, et al.
Publicado: (2019)

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
por: Traini, Chiara, et al.
Publicado: (2019)

Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
por: Lombardi, Giuseppe, et al.
Publicado: (2017)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2022)

Detrusor underactivity versus bladder outlet obstruction clinical and urodynamic factors
por: Kalil, Jefferson, et al.
Publicado: (2020)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Hui, C, et al.
Publicado: (2016)

CONCOMITANT DETRUSOR AND EXTERNAL URETHRAL SPHINCTER BOTULINUM TOXIN-A INJECTIONS IN MALE SPINAL CORD INJURY PATIENTS WITH DETRUSOR OVERACTIVITY AND DETRUSOR SPHINCTER DYSSYNERGIA
por: HUANG, Yu-Hui, et al.
Publicado: (2022)

Inosine Improves Neurogenic Detrusor Overactivity following Spinal Cord Injury
por: Chung, Yeun Goo, et al.
Publicado: (2015)

Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience
por: Mohanty, N. K., et al.
Publicado: (2008)

Sphingosine Kinase 1 urothelial expression is increased in patients with neurogenic detrusor overactivity
por: Ballouhey, Quentin, et al.
Publicado: (2015)

Adaptive changes of telocytes in the urinary bladder of patients affected by neurogenic detrusor overactivity
por: Traini, Chiara, et al.
Publicado: (2017)

AB204. Repeated intradetrusor botulinum toxin type A injections are still effective for patients with neurogenic detrusor overactivity secondary to spinal cord injury in China
por: Chen, Hui, et al.
Publicado: (2016)

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity
por: Sano, Yamato, et al.
Publicado: (2023)

Long-term follow-up after botulinum toxin A (BTX-A) injection into the detrusor for treatment of neurogenic detrusor hyperactivity in children
por: Zeino, Mazen, et al.
Publicado: (2012)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Nerve sprouting and neurogenic inflammation characterize the neurogenic detrusor overactive bladder of patients no longer responsive to drug therapies
por: Traini, Chiara, et al.
Publicado: (2019)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
por: Chen, Sheng-Fu, et al.
Publicado: (2020)

AB206. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
por: Chen, Hui, et al.
Publicado: (2016)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
por: Zhang, Rui, et al.
Publicado: (2015)

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin
por: Ferreira, Ana, et al.
Publicado: (2023)

Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo‐controlled, double‐blind trial with an open‐label extension
por: Honda, Masashi, et al.
Publicado: (2021)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study
por: Krebs, Jörg, et al.
Publicado: (2020)

Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
por: Yuan, Hejia, et al.
Publicado: (2017)

Abobotulinum - a toxin injection in patients with refractory idiopathic detrusor overactivity: injections in detrusor, trigone and bladder neck or prostatic urethra, versus detrusor - only injections
por: Emami, Maryam, et al.
Publicado: (2017)

Urinary ATP May Be a Dynamic Biomarker of Detrusor Overactivity in Women with Overactive Bladder Syndrome
por: Silva-Ramos, Miguel, et al.
Publicado: (2013)

Percutaneous tibial nerve stimulation in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: a historically controlled study
por: Carilli, Marco, et al.
Publicado: (2023)

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
por: Zhou, Xin, et al.
Publicado: (2015)

Semiconditional Electrical Stimulation of Pudendal Nerve Afferents Stimulation to Manage Neurogenic Detrusor Overactivity in Patients with Spinal Cord Injury
por: Lee, Young-Hee, et al.
Publicado: (2011)

Characterization of upper lamina propria interstitial cells in bladders from patients with neurogenic detrusor overactivity and bladder pain syndrome
por: Gevaert, Thomas, et al.
Publicado: (2011)

Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study
por: Baka‐Ostrowska, Małgorzata, et al.
Publicado: (2021)

BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study
por: Maignel, Jacquie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ppkt3nibur1jn23hgv151frfko